Upregulating the heme oxygenase (HO) system removes the prooxidant heme, and thus cytoprotective. Additionally, the products from the HO pathway including carbon monoxide, bilirubin and biliverdin scavenge reactive oxygen species, inhibit lipid peroxidation and suppress tissue inflammation, while the iron formed enhances the synthesis of the antioxidant, ferritin.
INTRODUCTION
The application of the synthetic mineralocorticoid, deoxycorticosterone acetate (DOCA) in combination with high salt intake to normotensive rats triggers severe hypertension that gradually leads to damage of the kidney, heart and vasculature (10, 24, 46) . Although unilaterally nephrectomized (UnX) DOCA-salt hypertensive rats have low renin (11) , the high levels of mineralocorticoid from the implanted DOCA strip mimics aldosterone overload, giving rise to a volume-dependent hypertension model that is also considered a model of human primary aldosteronism (10, 11, 24, 40, 43) . Aldosterone is a mineralcorticoid hormone secreted from the zona glomerulosa of the adrenal cortex in response to increased plasma levels of angiotensin-II or potassium. Although it is traditionally known to promote sodium retention, recent evidence indicate that aldosterone causes oxidative stress (16, 17) , and like angiotensin-II, stimulates inflammation and fibrosis by activating transcription factors such as nuclear factor kappaB (NF-κΒ) and activating protein (AP-1) (23, 30, 50) . Despite the low-renin, accumulating evidence indicates that local renin-angiotensin system (RAS) in the kidney contributes to renal injury of UnX-DOCA-salt hypertension by stimulating transforming growth factor (TGF-β1) and extracellular matrix (ECM) components like fibronectin (6, 16) . TGF-β1 is a potent cytokine that promotes cell proliferation and regulates the synthesis of the matrix-associated protein, fibronectin (6) , and is implicated in fibrosis and hypertrophy. Thus, the activation of TGF-β1, fibronectin, NF-κΒ and AP-1 constitutes a potent destructive force in tissues, especially in hypertensive conditions. Accordingly, mineralocorticoid overload in UnX-DOCA-salt hypertensive rats leads to severe renal histopathological lesions characterized by glomerulosclerosis, tubular fibrosis glomerular hypertrophy, tubular dilation, tubular cast, interstitial mononuclear infiltrations and tubular fibrosis (3, 46, 57) .
Many physiological systems are triggered in pathological conditions to counteract tissue insults. Among these is the heme oxygenase (HO) system, a pathway that could be pharmacologically modulated to alleviate tissue injury (4, 5, 15, 20, 22, 48, 49) . Ample evidence indicates that upregulating the HO system with HO inducers reduces oxidative stress, annul inflammation and lowers blood pressure (5, 22, 48, 49) . By breaking down the heme moiety, HO reduces tissue levels of heme, a prooxidant (20) . Moreover, the products from the HO system such as carbon monoxide, bilirubin and biliverdin are cytoprotective against apoptosis, inflammation and oxidative stress (5, 48, 49) while the iron formed enhances the synthesis of the antioxidant, ferritin (4, 15) . Seen in this light, carbon monoxide, bilirubin, bliverdin and ferritin constitute a protective tetrad that may combat hypertension, and secondarily-induced damage of hypertension resulting from elevated oxidative stress and inflammation (4, 5, 15, 20, 22, 48, 49) .
Given the availability of motifs for inflammatory and oxidative transcription factors like NF-κΒ and AP-1 in HO-1 gene promoter, the HO system may play an important role in cellular defence (28). Although the HO system is cytoprotective, the effects of the HO inducer, hemin, on renal injury in UnX-DOCA-salt rats have not been fully characterized. Importantly, the multifaceted interaction between the HO system, NF-κΒ and AP-1 in renal histopathological lesions such as glomerulosclerosis, glomerular hypertrophy, tubular dilation and the formation of tubular cast in mineralocorticoid-induced hypertension have not been reported.
The anti-fibrogenic properties of the HO system in the kidney has been acknowledged (32).
In a related study kidneys from HO-1 knockout mice were shown to express higher levels of fibronectin and interestingly, upregulating the HO system suppressed TGF-β 1 -mediated increase of fibronectin (32). Thus, the HO system may nullify renal fibrotic events that are mediated by TGF-β1 and fibronectin. However, it remains to be established whether the anti-fibrogenic effect of the HO system observed in mice is specie-dependent or a more-generalized phenomenon that could be applicable to kidney lesions in a model of human primary aldosteronism like UnX-DOCA-salt hypertensive rats. Therefore, the effect of the HO system on the expression of TGF-β1 and fibronectin in renal tissues of mineralocorticoid-induced hypertension will be investigated. Since cyclic guanosine monophosphate (cGMP) is one of the secondary messengers through which the HO system exerts its cytoprotective effects (38), we will also investigate whether this cyclic nucleotide is implicated in the amelioration of renal lesions. Thus, this study will unveil novel mechanisms by which the HO system alleviates renal injury in UnX-DOCA-salt hypertensive rats.
Mineralocorticoid-induced hypertension has been used extensively to study renal disease since this model is characterized histopathologically by severe renal lesions caused by aldosterone, NF-κΒ and AP-1 (3, 23, 30, 31, 34, 46, 50, 57) . Therefore, this model was chosen for our studies.
MATERIALS AND METHODS

The experimental protocol was approved by the University of Saskatchewan Standing
Committee on Animal Care and Research Ethics. Male Sprague Dawley (SD) rats of 8 weeks of age were purchased from Charles River Laboratories (Willington, MA, USA), and housed at 21°C with 12-hour light/dark cycles, fed with standard laboratory chow and had access to drinking water ad libitum. After a week of acclimatization UnX-DOCA-salt hypertension was performed as we previously described (19, 37) . Briefly, the right kidney of the animals were removed through a dorsal flank incision under isoflurane anaesthesia, and a silastic strip with or without DOCA was implanted subcutaneously in the mid-scapular region of the animals. Our experimental design included the following groups (n=7-26 per group): (A) controls [surgery-free or normal SD, UnXsham, UnX-salt (0.9%NaCl + 0.2% KCl) and UnX-DOCA]; (B) UnX-DOCA-salt hypertensive rats; (C) hemin-treated UnX-DOCA-salt; and (D) vehicle-treated UnX-DOCA-salt. The volume of each injection was 1ml. Hemin [(30 mg/kg, i.p.), Sigma St Louis, MO, USA) was dissolved in 0.1M NaOH, titrated to pH 7.4 with 0.1M HCl and diluted 1:10 with phosphate buffer as we previously reported (19, 37) .
Systolic blood pressure was determined by non-invasive tail-cuff method (Model 29 SSP, Harvard Apparatus, Montreal, Canada). The mean systolic blood pressure was calculated from six different measurements taken from each animal. A day prior to sacrifice, the animals were placed in metabolic cages for 24 hrs with free access to food and water/salt and urine samples collected. At the end of therapy, the animals were weighed, anaesthetized with pentobarbital sodium (50 mg/kg body wt), and samples of blood and tissue (kidney) were collected after decapitation. The tissues were cleaned in ice-cold phosphate-buffered saline (PBS), weighed and snap-frozen in liquid nitrogen. The PBS contained (mM) 140 NaCl, 3 KCl, 10 Na 2 HPO4, and 2 KH 2 PO4.
Histological, morphological and immunohistochemical analyses of kidney:
The left kidney was fixed in 10 % formalin buffer, processed and paraffin embedded, then sections of 5 μm thickness were cut. Some sections were stained with hematoxylin and eosin for histological studies while others were used for immunohistochemistry. From the cortical region of kidney sections, 30 glomeruli were randomly selected and the diameter determined by means of a computerized program using NIS-elements BR-Q imaging software (Nikon) [0.95 μm/Px] and average glomerular diameter were compared between different groups.
Morphologic evaluation of glomerular hypertrophy, glomerulosclerosis, tubular dilation, cast formation and mononuclear cell infiltration was conducted in a blind fashion using light microscopy semi-quantitatively with 0 to 3 scales (0, normal or almost normal; 1, mild; 2, moderate; 3, severe) in each kidney section and the mean score was calculated. Further assessment of renal lesions was done by counting the number of damaged and sclerotic glomeruli, and tubular protein casts in each section (57).
Immunohistochemistry assay was done by incubating some sections with serum to block non-specific staining, followed by overnight incubation with fibronectin antibody (1:250 dilution; P1H11 sc-18825, Santa Crutz Biotechnology Inc, CA, USA) or TGF-β1/2/3 antibody (1:100 dilution; H-112 sc-7892, Santa Crutz Biotechnology Inc, CA, USA). The TGF-β1/2/3 (H-112) antibody detects all three isoforms (TGF-β 1 , TGF-β 2 and TGF-β 3 ). Subsequently, the sections were treated with goat anti-mouse IgG for 30 min (1:200 dilution; Jackson ImmunoResearch Laboratories, Inc., Bar Harbor, ME, USA) and examined under a light microscope.
Immunohistochemical staining was done by means of the standard avidin-biotin complex method (Vector Laboratories). After thorough washing, the final detection step was carried out using 3,3'-diaminobenzidine (DAB; Sigma) as the chromogen. All sections were analyzed for staining using light microscopy and digitized using a high-resolution camera (Fujix HC-2000; Fujifilm, Tokyo, Japan). Quantitative assessment of fibronectin and TGF-β was performed in a blinded fashion by determining the gridded area of the kidney section occupied by the brown (DAB) staining. A score from 0-3 was given based upon the number of staining observed in a gridded area in the sections as follows: 0 = no staining, 1 = 1-3 areas, 2 = 4-7 areas, and 3 = 8 or more areas (57).
Determination of kidney hypertrophy
The kidney-to-body weight ratio is a widely accepted index of kidney hypertrophy (12) .
Body weights (BW) were recorded prior to sacrificing the animals. After anaesthesia, the left kidneys were rapidly removed from and placed in ice cold PBS, trimmed of fat and connective tissue, blotted and weighed using an analytical balance (Precisa XR 205SM-DR, Precisa Instruments Ltd, Switzerland). After weighing, the left kidney-to-body weight ratio was established.
Total RNA Isolation and Quantitative RT-PCR for p65-NF-κΒ and AP-1
Kidney tissues were homogenized in 0.5 ml Trizol Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) as we previously reported (19) . Reverse transcription was carried out using First Strand cDNA Synthesis Kit (Novagen, Madison, WI, USA) with 0.5 µg Oligo (dT)6, 50 mM Tris-HCl (pH 8.3 at 25ºC), 75 mM KCl, 75 mM KCl, 3 mM MgCl2, 50 mM DTT, 10 mM each free dNTP and 100 U of MMLV reverse transcriptase according to manufacturer's instruction. The program for thermal cycle was 10 min at 95°C followed by 40 cycles of 15 sec at 95°C, 30 sec at 56°C and 15 sec at 72°C. The melting points of PCR product were determined by incubating at 65°C for 1 min followed by a 1°C per min rise over 30 min.
Determination of HO activity and HO-1 assay
The HO activity was evaluated in kidney tissues as bilirubin production using our established method (19, 37) . The amount of bilirubin in each sample was determined by spectrophotometric assay, and expressed as nmole/mg protein/hour. The protein content was measured by Bradford. HO-1 concentration in kidney samples was determined by ELISA (EKS-810A, Stressgen-Assay Design, Ann Arbor, MI, USA) following the manufacturer's instructions.
Western Immunoblotting
The kidney was homogenized (1:10, w:v) in 10 mM Tris-buffered saline (20 mM Tris-HCl, pH 7.4, 0.25 M sucrose, and 1 mM EDTA) in the presence of a cocktail of protease inhibitors, and centrifuged as we previously described (19, 37) . In brief, proteins were extracted and quantified by Bradford assay, and aliquots of 50 μg were loaded on a 10% SDS-polyacrylamide gel for fibronectin and 12.5% for HO-1, HO-2 and TGF-β. The fractionated proteins were electrophoretically transferred to nitrocellulose paper and non-specific bindings blocked with 3% non-fat milk dissolved in PBS, and incubated overnight with primary antibodies against fibronectin Densitometric scanning and analyses of respective bands of blot was carried out using UN-SCAN-IT software (Silk Scientific, Utah, USA). A monoclonal mouse antibody raised against structural protein beta-actin (Sigma St Louis, MI, USA) (1: 5000 dilution) was used as a control to ascertain equivalent loading.
Determination of plasma ferritin, creatinine, sodium and urinary proteins
Plasma ferritin, sodium and urinary proteins were routinely measured by Saskatoon Royal University Hospital, Canada. Immediately on sacrifice, whole blood was collected in chilled 50 ml beakers containing heparin as anticoagulant. The whole blood was then centrifuged at 2000g at 4°C for 10 minutes. The resulting plasma was immediately removed by Pasteur pipette, dispensed into sample tubes for ferritin, creatinine and sodium measurement. A day prior to sacrifice, the animals were kept in metabolic cages for 24 hrs and urine samples collected, dispensed in tubes of 1 ml for the determination of proteinuria, albuminuria and creatinine. Creatinine clearance was calculated using the formula:
Determination of 8-isoprostane, an index of oxidative stress
Urinary 8-isoprostane is a non-invasive index of oxidative stress (9) . This was determined using a commercially available EIA kit (Cayman Chemical, Ann Arbor, MI). Briefly, urine samples were collected over a period 24 hrs were subsequently diluted 1:15 with ultra pure water, applied to a reverse-phase C-18 column at pH 3, and eluted with 1:1 (vol/vol) ethyl acetate/heptane. Thereafter, the eluent was further purified on a silica column and eluted with 1:1 (vol/vol) ethylacetate-methanol, and aliquoted in a 96-well plate that was pre-coated with monoclonal antibody. After, 8-isoprostane tracer and isoprostane antiserum were added to each well, incubated and after washing, Ellaman's reagent containing the substrate of acetylcholinesterase was added.
The absorbance were read at 412 nm in a plate reader (SpectraMax 340PC, Molecular Device, CA, USA), and the values of 8-isoprostane calculated from a standard curve.
Measurement of cGMP content
The concentration of cGMP was assessed by EIA (Cayman Chemical, Ann Arbor, MI) after extraction from tissues as previously described (19, 37) . Briefly, the kidney samples were homogenized in 6% trichloroacetic acid at 4°C in the presence of 3'-isobutil-1-methylxanthine to inhibit phosphodiesterase activity and centrifuged at 2000 g for 15 minutes. The supernatant was recovered, washed with water-saturated diethyl ether and the upper ether layer was aspired and discarded while the aqueous layer containing cGMP was recovered and lyophilized. The dry extract was dissolved in assay buffer and the cGMP content was measured using the manufacturer's protocol and expressed as picomol of cGMP per mg of protein.
Total antioxidant capacity assay
The total antioxidant capacity assay was done by EIA (Cayman Chemical, Ann Arbor, MI, USA) as we previously reported (19, 37) . In tissues, the antioxidant system comprises different enzymes including superoxide dismutase, catalase, and glutathione peroxidise as well as substances like ferritin, ascorbic acid, α-tocopherol, β-carotene, reduced glutathione, uric acid, biliverdin, bilirubin etc (2, 4, 5, 15, 20, 48, 49) . The sum of endogenous and food-derived antioxidants represents the total antioxidant activity of the system. The additive effect of all the different antioxidants provides greater protection against oxidative stress than any single compound alone.
The Cayman Chemical Antioxidant Assay Kit measures the total antioxidant capacity (2, 27 ). This assay is based on the ability of the anti-oxidants in samples to inhibit the oxidation of 2,2'-azino-di- 
Statistical Analyses
All data was expressed as mean ± SEM and analyzed using Student's t test and analysis of variance in conjunction with Bonferroni test for multiple comparisons. Additionally, Spearman
Correlation and Linear-by-Linear Association analyses were used to compare the different variables in some cases. Group differences at the level of p < 0.05 were considered statistically significant.
RESULTS
Hemin therapy reduced blood pressure and abates kidney hypertrophy in UnX-DOCA-salt rats
As expected, the implantation of DOCA strips to normotensive UnX rats that were given salt water (0.9%NaCl + 0.2% KCl) resulted in hypertension (190 mmHg), whereas the controls including, UnX-sham, UnX-salt, UnX-DOCA and surgery-free SD had normotensive blood pressure of 121, 119, 121 and 116 mmHg respectively. The 4-week hemin therapy to UnX-DOCAsalt hypertensive rats significantly lowered blood pressure (190 vs. 135 mmHg; n=22, p<0.01) (Fig.   1A) . At the end of first week, blood pressure dropped from 190 to 180 mmHg, and progressively decreased after the 2 nd , 3 rd , and 4 th week to 168, 152 and 135 mmHg respectively. Accordingly, the elevation of blood pressure in UnX-DOCA-salt-rats was attenuated by hemin by 5.8, 7.5, 10.2, and 12.5% respectively after week 1, 2, 3, and 4 of therapy. The vehicle did not affect blood pressure, kidney hypertrophy or any other parameter studied ( Fig. 1A and Table 1 ). The reduction of blood pressure in UnX-DOCA-salt hypertensive rats was accompanied by suppression of kidney hypertrophy (7.5±0.3 (n=22) vs. 6.1±0.1 (n=26) g/kg body wt, p<0.01) (Fig. 1B) . Although hemin therapy reduced hypertrophy in UnX-DOCA-salt hypertensive rats, it did not restore similar values as observed in the normotensive control groups (sham-operated and surgery-free SD), and thus was only partially effective. However, the magnitude of reduction was very significant, given that 19.7% decrease was observed. Although our results indicate that hemin has both anti-hypertensive and anti-hypertrophic effects, hemin therapy was more effective as an anti-hypertensive agent since it restored blood pressure to physiological levels in UnX-DOCA-salt rats but failed to reinstate hypertrophy to the level of age-matched normotensive animals.
Our results also indicate that fluid intake was significantly elevated in UnX-DOCA-salt hypertensive animals as compared to the controls (Table 1) . Interestingly, hemin therapy significantly reduced fluid intake in UnX-DOCA-salt hypertensive rats. Similarly, hemin abated important indices of renal damage like proteinuria/albuminuria and creatinine clearance (3),
although control values (sham-operated and normal SD) were not reinstated ( Table 1) .
Hemin had no effect on body weight but reduced the hematocrit value of UnX-DOCA-salt hypertensive rats ( Table 1) . Although reduced hematocrit may affect blood pressure, it is difficult
to say to what extent it contributed to the antihypertensive effect. Further investigations should be carried out to address the reduction of hematocrit.
The hemin regimen upregulates HO activity, cGMP and ferritin levels
To elucidate the mechanisms responsible for the renoprotective and antihypertrophic effect of hemin, HO activity was assayed. HO activity includes the contribution from different isoforms including HO-1 and HO-2. The basal expression of HO-1 (inducible isoform) was similar in the sham-operated and normal SD controls, but lower than the levels of UnX-DOCA-salt hypertensive rats. Hemin therapy greatly enhanced the HO-1 expression of DOCA-hypertensive rats by 1.8-fold ( Fig. 2A) . A similar trend was observed with HO-1 concentration, where comparable basal control levels that were lower than those of UnX-DOCA-salt rats were detected. Hemin therapy markedly increased the levels of HO-1 in UnX-DOCA-salt rats by 3.4 fold (Fig. 2B) . On the other hand, the basal expression of HO-2 (constitute isoform) were similar in the controls and UnX-DOCA-salt hypertensive rats, and remained unchanged after hemin therapy (Fig. 2C) . The lack of induction of HO-2 by hemin is consistent with previous studies that have shown that this constitutive isoform is not inducible (39). Since HO-1 expression and concentration were upregulated by hemin, we assayed HO activity to assess whether the hemin-induced changes in HO-1 would be accompanied by a parallel change in HO activity. The results indicate that the basal levels of HO activity in normal SD and sham-operated rats were similar, but those of UnX-DOCA-hypertensive rats were higher than the normotensive controls. The administration of hemin to UnX-DOCA-salt rats markedly enhanced HO activity by 4-fold (Fig. 2D) . The enhanced HO activity will increase the production of endogenous carbon monoxide, that will in turn stimulate guanylate cyclase-cGMP pathway (39). Correspondingly, a robust increase in cGMP content was detected in hemin-treated animals ( Fig. 2E) . Importantly, the elevation of cGMP is an important mechanism responsible for the attenuation of glomerular sclerosis (42, 56). Although the basal HO activity in UnX-DOCA-salt hypertensive rats were higher than controls, it may was not sufficient to evoke changes in cGMP content as the basal levels of cGMP in UnX-DOCA-salt and controls were comparable. We had previously reported a similar observation in spontaneously hypertensive rats as well as in UnX-DOCA-salt hypertension (19, 37, 39) .
Given that ferritin, an antioxidant is amongst the cytoprototective products of the HO system (4, 15), we examined the effect of hemin therapy on ferritin levels. In UnX-DOCA-salt hypertensive rats, the basal level of the ferritin was lower than in the control animals. Interestingly, the administration of hemin markedly increased ferritin concentration by 2.7 fold (Fig. 2F) .
The effect of hemin therapy on oxidative stress, NF-κΒ and AP-1 in UnX-DOCA-salt hypertensive rats
Inflammatory and oxidative insults are common events in hypertrophy (23) . In UnX-DOCAsalt hypertensive rats, the levels of 8-isoprostane, a marker of oxidative stress (9) were significantly elevated as compared to the normotensive controls (Fig. 3A) . (Fig. 3B) . Importantly, the suppression of oxidative stress in UnX-DOCA-salt hypertensive rats coincided with decreased NF-κΒ and AP-1. Our quantitative RT-PCR assay indicated that the basal mRNA expression of the pro-inflammatory transcription factor, NF-κΒ in sham-operated and normal SD control rats were comparable, whereas the levels in UnX-DOCA-salt hypertensive rats were enhanced by 3-fold. As illustrated in Figure 3D , the suppression of oxidative stress and hypertrophy by hemin was accompanied by the reduction of NF-κΒ (Fig.   3C) . Similarly, the basal mRNA expression levels of AP-1, another transcription factor that mediates oxidative stress and inflammatory events (30) were 3.5 fold higher in UnX-DOCA-salt hypertensive rats. Importantly, hemin therapy significantly abated AP-1 (Fig. 3C) . Although hemin therapy greatly potentiated the anti-oxidant status, and reduced oxidative stress in UnX-DOCA-salt hypertensive rats, AP-1 and NF-κΒ were not restored to sham-operated or normal SD control levels ( Figs. 3C and 3D) . Nevertheless, in hemin-treated animals, the magnitude of reduction of AP-1 and NF-κΒ were 33.7 % and 29.2% respectively.
Further assessment of our results by Spearman's analyses indicated a strong positive correlation between the mRNA levels of AP-1 and NF-κB (r=0.982, p=0.0001), and renal histopathological lesions of UnX-DOCA-salt hypertensive rats. In contrast, Spearman's analyses revealed that there is a negative correlation between AP-1 and total antioxidant capacity (-0.417), as well as between NF-κΒ and total antioxidant capacity (-0.45).
Hemin therapy suppresses the expressions of TGF-β and fibronectin
The protective effect of hemin therapy on UnX-DOCA-salt-induced renal lesions was further verified by immunostaining of kidney sections of TGF-β and fibronectin. TGF-β is implicated in a variety of kidney diseases where it promotes the deposition of extracellular matrix proteins including fibronectin (32). Interestingly, hemin therapy concomitantly reduced the expression of TGF-β and fibronectin. Figure 4A shows representative images of fibronectin immunostaining. The sham-operated rats were almost devoid of fibronectin positive stainings. In
UnX-DOCA-salt hypertensive rats, there was increased fibronectin positive stains depicting damage around the tubules, connective tissue and blood vessels (Fig. 4A) . However, the application of hemin therapy to UnX-DOCA-salt hypertensive rats significantly reduced the positive stains of fibronectin, although control levels were not attained (Fig. 4C) . Hemin treatment also decreased the quantitative score of fibronectin in UnX-DOCA-salt hypertensive rats (Fig. 4E) , although it did not reinstate the levels of sham-operated control. Correspondingly, Western immunoblot and the relative densitometric analysis showed that hemin therapy significantly reduced fibronectin levels in UnX-DOCA-salt hypertensive rats (Fig. 4E) . The basal protein expression of fibronectin in UnX-DOCA-salt hypertensive rats were significantly elevated as compared to the sham operated-control, but hemin abated fibronectin to levels even lower than in the sham-operated control. Figure 4B shows representative images of TGF-β immunohistochemical staining. A few positive staining were found in tubular epithelial cells of sham-operated control animals (Fig. 4B) .
In UnX-DOCA-salt hypertensive rats, the number of positive staining greatly increased and many damaged tubules were noted. Importantly, the damaged tubules were very numerous, and large in size, and very conspicuous. The application of hemin to UnX-DOCA-salt hypertensive rats resulted in significant reduction of TGF-β positive staining, and the number and size of damaged tubules were greatly reduced. However, hemin therapy did reduce the damages to sham-operated control levels (Fig. 4B) . Our results also indicate a significant reduction of the quantitative score of TGF-β in hemin-treated UnX-DOCA-salt rats (Fig. 4D) , even though sham-operated control values were not obtained. The hemin-induced reduction of TGF-β positive staining was consistent with our
Western blot data which revealed significant depletion of TGF-β in UnX-DOCA-salt rats (Fig. 4D) .
A comparison between our Western blot and immunohistochemical data revealed different effectiveness of hemin against fibronectin and TGF-β in UnX-DOCA-salt rats. Western blot indicated that hemin was more effective in suppressing fibronectin and TGF as the levels of expression of these proteins after hemin therapy were comparable or even lower than in the shamoperated control whereas, our immunohistochemical data showed that hemin did not reinstate shamoperated control levels. The reason for this discrepancy is unclear and should be further investigated.
Hemin therapy reduces histopathological evidence of kidney damage
Hemin therapy reduced renal lesions, including glomerular hypertrophy, glomerulosclerosis, tubular dilation, tubular-cast formation and interstitial mononuclear cell-infiltration in UnX-DOCAsalt hypertension. The assessment of our results by Spearman's analyses revealed positive correlation between the high levels of NF-κB in UnX-DOCA-salt hypertension and glomerulosclerosis (r=0.662, p=0.026) (Fig. 5A) , tubular dilation (r=0.751, p=0.008) (Fig. 5A) , damaged glomeruli (r=0.647, p=0.031) (Fig. 5B) , and glomerular diameter (r=0.627, p=0.039) (Fig.   5C ). Interestingly hemin therapy reduced these lesions, although only partially in some cases. For example sclerotic/damaged glomeruli, and tubular cast (Fig. 5D) were not restored to the control levels. The reason for this selective effect is unclear, and should be further investigated.
Further assessment of our results by Spearman's analyses revealed that high levels of AP-1
in UnX-DOCA-salt hypertension correlates with glomerulosclerosis (r=0.662, p=0.026), tubular dilatation (r=0.808, p=0.003), tubular casts (r=0.642, p=0.033), glomerular damage (r=0.706, p=0.015) and glomerular diameter (r=0.664, p=0.026). All these histological defects were reduced in hemin-treated animals (Fig. 5) . Analogically, Linear-by-Linear Association analyses indicated that tubular dilation correlates with tubular casts (p=0.022), glomerular hypertrophy (p=0.034), glomerulosclerosis (p=0.019) and glomerular diameter (p=0.008) in UnX-DOCA-salt hypertensive animals, and these structural defects were attenuated by hemin therapy (Figs. 5 and 6) . Similarly, we also observed reduced interstitial mononuclear cell infiltration in hemin-treated animals (Fig. 6) .
Finally, morphological analyses confirmed the suppression of renal tissue in hemin-treated animals ( Table 2) .
DISCUSSION
The present study demonstrates that hemin is a potent renoprotective substance capable of reducing elevated blood pressure, attenuating kidney lesions, suppressing hypertrophy, decreasing albuminuria, proteinuria, and creatinine clearance in UnX-DOCA-salt hypertension, a model of volume-overload. In UnX-DOCA-salt induced hypertension, aldosterone overload triggers oxidative stress, inflammatory insults and fibrosis by activating NF-κΒ and AP-1 transcription factors (10, 11, 16, 17, 23, 24, 30, 40, 43, 50) . Therefore, the high levels of 8-isoprostane, a marker of oxidative stress, alongside enhanced levels of NF-κΒ and AP-1 observed in UnX-DOCAhypertensive rats may be reflective of elevated oxidative stress. The activation of NF-κΒ and AP-1 plays significant pathophysiological role in renal injury (23, 30, 34, 50) . In UnX-DOCA-salt hypertensive animals, severe renal lesions, including elevated glomerulosclerosis, glomerular hypertrophy, tubular cast, interstitial mononuclear infiltrations, tubular fibrosis and tubular dilation were observed. These lesions were accompanied by significant elevation of proteinuria and albuminura, alongside reduced creatinine clearance. Moreover, increased excretion of urinary proteins may be indicative of kidney injury, secondary to increased glomerular pressure in the setting of volume-overload hypertension, which is characteristic of the UnX-DOCA-salt model (11, 43) . Interestingly, the administration of hemin significantly attenuated the renal lesions.
Importantly, the suppression of renal lesions in hemin-treated animals was accompanied by a corresponding decline of urinary proteins with significant improvement of creatinine clearance. increased NF-κΒ activity has been shown to coincide with histological evidence of kidney damage (14) , which is also confirmed by our study. As NF-κΒ regulates the expression of many genes involved in inflammatory responses (26) , the lower levels of NF-κΒ in hemin-treated animals detected in our study may be reflective of decreased interstitial inflammation and glomerulosclerosis. Similarly, AP-1 activity has been reported to increase during the development of glomerular and tubulo-interstitial lesions in hypertension, polycystic kidney disease and glomerulonephrities (8, 13, 41, 44) , suggesting that AP-1 may be a major determinant of renal injury. Accordingly, the decreased levels of AP-1 observed in our study may account for the reduced renal lesions after hemin therapy. Thus, our study indicates that the suppression of renal histopathological damage including glomerulosclerosis, glomerular hypertrophy, tubular dilation, tubular cast-formation, alongside decreased interstitial mononuclear cell-infiltrations in hemintreated animals may be attributed to the concomitant attenuation of TGF-β1, fibronectin, NF-κB and AP-1, with corresponding decline of oxidative and inflammatory cascades. The improved functional status of the kidneys after hemin therapy was associated with reduced proteinuria/albuminuria and increased creatinine clearance. Therefore, a multifaceted interaction between the HO system, TGF-β1, fibronectin, AP-1 and NF-κB may be explored to design new drugs against end-stage organ damage in hypertension.
Our study also confirmed that hemin therapy increased cGMP levels in UnX-DOCA-salt rats. Interestingly, cGMP is known to abate inflammation and glomerulosclerosis in chronic renal disease (42). Moreover, a cGMP-dependent mechanism has been shown to suppress both AP-1 and NF-κB in ischemia and reperfusion injury (25) . Therefore, the enhanced cGMP levels observed in our study alongside the suppression of TGF-β1, fibronectin, AP-1 and NF-κB activities constitutes part of the multifaceted mechanisms against inflammatory and oxidative cascades by which hemin therapy annuls renal lesions. However, this phenomenon should be further investigated in other tissues and strains to ascertain its universality.
Another key observation is that the 4-week hemin regimen was more effective as an antihypertensive agent since it lowered blood pressure to physiological levels, but only partially suppressed kidney hypertrophy. However, a 19.7% decrease of kidney hypertrophy in UnX-DOCA-salt hypertension was accompanied by reduced kidney lesions and improved renal function that was reflected by the lower levels of urinary proteins and increased creatinine clearance. Although the overall protective effect was appreciable, the reasons for the different efficacy against hypertension and hypertrophy remains poorly understood, and should be further investigated. However, since hypertrophy is a structural adaptation it may not be completely reversed within the relatively short time-frame that this study was carried out. Given that hemin has recently been shown to evoke sustained antihypertensive effects (55), it possible that further reduction of kidney hypertrophy may be observed during the longer time-frame that physiological blood pressure is maintained. Although hemin attenuated the initial rise in blood pressure, hemin appeared to be more effective at the later stages, suggesting that sodium retention might be among the mechanisms involved at that the initial stage of therapy, while at later stages mechanisms that attenuate structural damages became more predominant. However, the simultaneous involvement of the different mechanisms at varying degree at each phase of therapy cannot be ruled out. This notion is sustained by the observation of reduced plasma sodium alongside the suppression of renal lesions at the time of sacrifice of the animals (4 weeks of therapy). Importantly, the reduction of plasma sodium was accompanied by a parallel reduction of fluid intake. One limitation of our study is the lack of molecular, biochemical and histological data at the different-time point of therapy. Therefore, future studies designed to quantify the relative input of each mechanism will be needed for a more comprehensive understanding.
Many studies have reported the anti-hypertensive and cytoprotective effects of hemin and the products of the HO system like bilirubin, ferritin and carbon monoxide (5, 48, 49) . However, carbon monoxide was recently shown to interfere with the vasodilatory effects of the nitric oxide (52), and promoting endothelium-dependent vasoconstriction in isolated gracilis muscle arterioles of UnX-DOCA-salt rats (21). These paradoxical effects may be due to the biphasic effect of carbon monoxide, and therefore the specific conditions under which different experiments are carried out may be critical to the observed effect. In our setting, it is possible that hemin therapy potentiated the HO system, that in turn increased endogenous carbon monoxide alongside bilirubin and ferritin that would act in concert to lower blood pressure, suppress oxidative stress and inflammation by increasing cGMP, and abating NF-κΒ and AP-1.
Collectively, our results demonstrate the potent renoprotective effect of hemin therapy. The anti-oxidant and anti-inflammatory effect of hemin observed in our study will combine with the cytoprotective effects of the other components of the HO system (bilirubin, biliverdin and ferritin)
to protect the kidneys against histological lesions, fibrosis and hypertrophy. As hemin therapy suppresses histopathological lesions that generally characterize the progression of end-stage kidney damage, a central role of the HO system in renoprotection is envisaged. Since oxidative and inflammatory insults are involved in renal lesions, our results may be correlated with human data to provide more information at cellular level which could be beneficial to humans (54). Thus, our findings may be of clinical relevance, and have great translational potential given that the FDA has approved hemin therapy against porphyria (7). all other groups). Treatment with hemin reduced kidney hypertrophy, whereas the vehicle had no effect ( † p<0.01 vs. UnX-DOCA-salt or UnX-DOCA-salt-vehicle). Bars represent means ± SE. 
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